Novogenia AG, an international healthcare company focused on human genetics and personalized health products, has published its issuer report for the first half of 2026, revealing a 7% decline in consolidated revenue to EUR 25.7 million compared to EUR 26.5 million in the prior-year period. The decline was primarily attributed to lower volumes in the pharmaceutical and medical device trading segment due to regulatory changes, while the DNA analysis and personalized products segment posted positive revenue growth. The report, announced via NEWMEDIAWIRE, highlights both challenges and strategic progress as the company works to strengthen its core business.
CEO Dr. Daniel Wallerstorfer acknowledged that financial performance did not meet expectations in all areas. “We have not yet been able to realize our ambitious growth plans,” he said. “However, we are encouraged by the positive year-on-year development of our core business in DNA analyses and personalized health products, as well as by a significant reduction in our cost base.” The company achieved cost savings in materials, personnel, and other operating expenses, leading to an improvement in operating profit of approximately EUR 2.7 million. However, due to a decline in other operating income, operating result (EBIT) improved only 4.1% to EUR -4.7 million. Consolidated net income was EUR -2.1 million, compared to EUR 2.0 million in the prior year, which had benefited from a significantly higher financial result. As of June 30, 2026, Novogenia held EUR 39.8 million in cash and cash equivalents, down from EUR 71.9 million, but remains in a solid financial position to drive further development.
Strategically, Novogenia made significant progress in the first half of 2026. The company expanded its collaboration with 10X Health Systems, advanced preparations for a Middle East market launch with G42 in Abu Dhabi, and launched the enhanced Methylation Test MGT Plus in the U.S. It also introduced the Multi-Cancer Check and a new software platform for its NovoDaily product line. Construction of a new company site in Hallwang near Salzburg commenced, with completion planned for early 2028. The facility will cover more than 9,300 square meters and provide modern laboratory and production capacities. Additionally, the renaming from Darwin AG to Novogenia AG was implemented in July 2026, consolidating brand identity and strengthening visibility with customers and investors.
Novogenia will engage with investors at several upcoming conferences, including the 5th Zurich Investor Day on September 29, the Abu Dhabi Future Health Summit from October 20-22, the ODDO BHF Autumn Round Table on October 22, and the Deutsches Eigenkapitalforum from November 23-25. These events underscore the company’s commitment to international growth and investor communication. The full issuer report is available on www.newmediawire.com.
The implications of Novogenia’s H1 2026 report are significant for the personalized healthcare industry. While regulatory changes in the pharmaceutical trading segment weighed on overall revenue, the growth in DNA analysis and personalized products demonstrates rising demand for genetic-based health solutions. The company’s cost reduction efforts and strategic partnerships position it to capitalize on this trend. As Novogenia mitigates the impact of digital platform algorithm changes on its sales channels, its ability to innovate and expand internationally will be crucial. The upcoming product launches and Middle East market entry could drive future growth, making Novogenia a company to watch in the evolving landscape of personalized prevention and healthcare.
